Vasopeptidase Inhibition Attenuates Proteinuria and Podocyte Injury in Zucker Diabetic Fatty Rats

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2007 Mar 3

PMID 17333128

Citations 3

Authors

Sabine Fredersdorf

Joachim Weil

Coskun Ulucan

Christoph Birner

Roland Buttner

Thomas Schubert

Carsten A Boger

Kurt Debl

Frank Muders

Gunter A Riegger

Andreas Luchner

Affiliations

Soon will be listed here.

Abstract

Inhibition of the renin angiotensin aldosterone system (RAAS) produces protective effects on cardio-renal injury in type 2 diabetes. Vasopeptidase inhibitors (VPI) represent a new pharmacological tool, acting by simultaneous inhibition of the RAAS and neutral endopeptidase. We examined the effects of chronic VPI on renal function and morphology in experimental type 2 diabetes as compared to angiotensin converting enzyme inhibition (ACE-I). Zucker diabetic fatty rats aged 13 weeks were treated with either VPI (AVE7688, ZDF-VPI, n = 8) or ACE-I (Ramipril, ZDF-ACE-I, n = 7) or placebo (ZDF, n = 8). Heterozygous rats served as non-diabetic controls (Ctr, n = 8). Both treatments led to a similar decrease in blood pressure. After 10 weeks of treatment, ZDF developed marked albuminuria. The latter was significantly attenuated in ZDF-VPI as compared to ZDF and ZDF-ACE-I. Renal histology revealed a significant expansion in the glomerular tuft area in all ZDF groups. However, expression of glomerular desmin, which has been recognized as a sensitive marker of early podocyte damage, was significantly increased in ZDF as compared to Ctr. Desmin was reduced in ZDF-VPI but not in animals treated with ACE-I. There was a correlation between albumin excretion and desmin-positive glomerular area. In experimental type 2 diabetes, albuminuria correlates to podocyte damage. These hallmarks of diabetic nephropathy are attenuated by VPI to a greater extent than by ACE-I alone. These findings suggest that podocyte damage is an early critical step in the progression of diabetic nephropathy, and that VPI is a promising pharmacological tool in the treatment of diabetic renal disease.

Citing Articles

Overexpression of Mafb in podocytes protects against diabetic nephropathy.

Morito N, Yoh K, Ojima M, Okamura M, Nakamura M, Hamada M J Am Soc Nephrol. 2014; 25(11):2546-57.

PMID: 24722438 PMC: 4214526. DOI: 10.1681/ASN.2013090993.

Losartan reverses glomerular podocytes injury induced by AngII via stabilizing the expression of GLUT1.

Yu S, Qi R, Zhao H Mol Biol Rep. 2013; 40(11):6295-301.

PMID: 24062074 DOI: 10.1007/s11033-013-2742-9.

Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice.

Zhang H, Schin M, Saha J, Burke K, Holzman L, Filipiak W Am J Physiol Renal Physiol. 2010; 299(1):F91-8.

PMID: 20375116 PMC: 2904178. DOI: 10.1152/ajprenal.00021.2010.

References

. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-9. View

Boger C, Gotz A, Kruger B, Hosl M, Schmitz G, Riegger G . Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Eur J Med Res. 2005; 10(4):161-8. View

Sasaki T, Jyo Y, Tanda N, Kawakami Y, Nohno T, Tamai H . Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy. Kidney Int. 1997; 51(1):301-9. DOI: 10.1038/ki.1997.37. View

Bonventre J, Force T . Mitogen-activated protein kinases and transcriptional responses in renal injury and repair. Curr Opin Nephrol Hypertens. 1998; 7(4):425-33. DOI: 10.1097/00041552-199807000-00013. View

Floege J, Hackmann B, Kliem V, Kriz W, Alpers C, Johnson R . Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int. 1997; 51(1):230-43. DOI: 10.1038/ki.1997.28. View

Burnett Jr J . Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999; 17(1):S37-43. View

Schafer S, Linz W, Vollert H, Biemer-Daub G, Rutten H, Bleich M . The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia. 2003; 47(1):98-103. DOI: 10.1007/s00125-003-1264-8. View

Gades M, Stern J, van Goor H, Nguyen D, Johnson P, Kaysen G . Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int. 1998; 53(1):130-5. DOI: 10.1046/j.1523-1755.1998.00746.x. View

Hiromura K, Haseley L, Zhang P, Monkawa T, Durvasula R, Petermann A . Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int. 2001; 60(6):2235-46. DOI: 10.1046/j.1523-1755.2001.00057.x. View

10.

Meyer T, BENNETT P, Nelson R . Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia. 1999; 42(11):1341-4. DOI: 10.1007/s001250051447. View

11.

Cao Z, Burrell L, Tikkanen I, Bonnet F, Cooper M, Gilbert R . Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001; 60(2):715-21. DOI: 10.1046/j.1523-1755.2001.060002715.x. View

12.

Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R . Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998; 128(12 Pt 1):982-8. DOI: 10.7326/0003-4819-128-12_part_1-199806150-00004. View

13.

Gross M, Heiss N, Weckbach M, Hansen A, El-Shakmak A, Szabo A . ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes. Diabetologia. 2004; 47(2):316-24. DOI: 10.1007/s00125-003-1309-z. View

14.

Quaschning T, dUscio L, Shaw S, Luscher T . Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension. 2001; 37(4):1108-13. DOI: 10.1161/01.hyp.37.4.1108. View

15.

Appel R . Mechanism of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogenesis. Am J Physiol. 1990; 259(3 Pt 1):E312-8. DOI: 10.1152/ajpendo.1990.259.3.E312. View

16.

Gambaro G, DAngelo A, Del Prete D, Ceol M, Garbisa S, BERTAGLIA G . Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin. Am J Nephrol. 1999; 19(4):530-4. DOI: 10.1159/000013495. View

17.

Wiggins J, Goyal M, Sanden S, Wharram B, Shedden K, Misek D . Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005; 16(10):2953-66. DOI: 10.1681/ASN.2005050488. View

18.

Buschhausen L, Seibold S, Gross O, Matthaeus T, Weber M, Schulze-Lohoff E . Regulation of mesangial cell function by vasodilatory signaling molecules. Cardiovasc Res. 2001; 51(3):463-9. DOI: 10.1016/s0008-6363(01)00340-6. View

19.

Lingohr M, Buettner R, Rhodes C . Pancreatic beta-cell growth and survival--a role in obesity-linked type 2 diabetes?. Trends Mol Med. 2002; 8(8):375-84. DOI: 10.1016/s1471-4914(02)02377-8. View

20.

Phillips M, Liu Q, HAMMOND H, Dugan V, Hey P, Caskey C . Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet. 1996; 13(1):18-9. DOI: 10.1038/ng0596-18. View